[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100435928":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":28,"locations":34,"responsibleParty":47,"collaborators":27,"id":49,"slug":27,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":27,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":27,"enrollmentInfo":57,"targetDuration":27,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":27,"overallStatus":68,"whyStopped":27,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"Peking University Third Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"VBT","EXPERIMENTAL","CT image guided high-dose-rate vaginal brachytherapy, 30Gy\u002F6f, 2f\u002Fw.",[13],"Radiation: vaginal brachytherapy\u002Fpelvic external beam radiotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"EBRT","ACTIVE_COMPARATOR","Pelvic external beam radiotherapy，IMRT\u002FVAMT，IGRT suggested，DT 45Gy\u002F25f.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"RADIATION","vaginal brachytherapy\u002Fpelvic external beam radiotherapy","high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy",[15,9],[26],"Pelvic external beam radiotherapy",null,[29],{"name":30,"role":31,"phone":32,"phoneExt":27,"email":33},"Junjie Wang","CONTACT","861082265920","junjiewang_edu@sina.cn",[35],{"facility":36,"status":27,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":27},"Peking University 3rd Hospital","Beijing","Beijng","100191","China",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},{"type":48,"investigatorFullName":30,"investigatorTitle":5,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"PRINCIPAL_INVESTIGATOR","100435928",false,"NCT04956601","Adjuvant Radiotherapy in Patients With Early Endometrial Cancer","A Multicenter, Randomized, Controlled Trial of Adjuvant Radiotherapy in Patients With Early Endometrial Cancer Based on Moderate Risk Molecules Classification","Inclusion Criteria:\n\n1. Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were microsatellite instability type and low copy type;\n2. Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space invasion;\n3. Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional;\n4. ECOG score is 0-2;\n5. The interval time between surgery and radiotherapy is no more than 8 weeks;\n6. The routine blood examination was normal;\n7. Compliance is good and informed consent is voluntarily signed.\n\nExclusion Criteria:\n\n1. The patients receive chemotherapy;\n2. History of previous malignant disease;\n3. Previous diagnosis of Crohn's disease or ulcerative colitis.","FEMALE","18 Years",{"count":58,"type":59},480,"ESTIMATED","INTERVENTIONAL",[62],"NA","To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when compared to pelvic external beam radiotherapy in patients with early endometrial cancer based on moderate risk molecules classification.",[65,66,67],"Endometrial Cancer","Pathology","Radiotherapy","NOT_YET_RECRUITING","2021-07-02",{"date":71,"type":72},"2021-07-09","ACTUAL",{"date":74,"type":59},"2021-07",{"date":76,"type":59},"2029-08",{"name":5,"class":6},1]